MONTREAL, June 16 /CNW Telbec/ - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company developing high-value human
plasma-derived protein products for commercialization, announces that it has
raised $7.8 million through the exercise of amended Series B warrants and
broker warrants issued as part of the private placement concluded in January
2007.
